CEO of CNS Bioscience, Inc., Matthew Autterson

Matthew Autterson attended and graduated from Michigan State University in 1980 with a BA in Finance. Autterson also held positions as a member of the Young Presidents Organization and the World Presidents Organization. He later attended the University of Denver Graduated Tax Program, and jumped off his career at First Trust Corporation, a subsidiary of Fiserv. After two years, Matthew left his position with First Trust Corporation in 1982 to join a small team seeking to charter a new Colorado State chartered trust company as a subsidiary of New York-based financial services company Integrated Resources, Inc. By 1986, he’d become president of Resources Trust Company. Three years later, Resources Trust Company, as well as other assets owned by Integrated Resources, Inc., was sold to Broad, Inc. Broad, Inc., would then become SunAmerica, Inc., which would then be acquired by AIG in 1998 for $18 billion. In 2001, Fiserv acquired Resources Trust Company from AIG. Prior to the sale, Resources Trust Company had become one of the largest state-charted, FDIC-insured depository trust companies in the entire United States, with its depository and custodial services totaling over 200,000 clients, brought in by its over 15,000 registered independent financial advisors. It held more than $20 billion in custodial assets, as well as more than $1 billion in deposits.

After years as a leader in Colorado’s business community, serving on the Board of the Denver Zoo, and Denver Zoological Foundation, the Webb-Waring Foundation, and as Chairman of the Board of Directors of Denver Hospice, Autterson pursues his philanthropic interests represented by FAB. He is currently a member of the Board of Directors of Falci Adaptive Biosystems (FAB), headed by Scott Falci, M.D., which helps people suffering from neuromotor disabilities to increase their ability to control and interact with their environment. Autterson is also on the Board of Directors as President and CEO of CNS Bioscience, Inc., a clinical-stage drug development company that focuses on alleviation of neuropathic pain, founded by Falci in 2013, furthering the potential to help those with spinal cord injuries. Matthew Autterson continues to play key roles in his community by participating in running events as well as giving us a lovely nature quote on Twitter, every day.


August 30, 2017

Posted In: Bioscience

Leave a Comment